Effects of Resveratrol on the Treatment of Inflammatory Response Induced by Severe Burn

Inflammation

Volumn 38, Issue 3, 2015, Pages 1273-1280

  Tao, Ke ^a   Bai, Xiaozhi ^a   Jia, Wenbin ^a   Liu, Yang ^a   Zhu, Xiongxiang ^a   Han, Juntao ^a   Dong, Maolong ^a   Li, Jun ^a   Chen, Dongdong ^b   Hu, Dahai ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Neurology   (China)

Author keywords

macrophage; pro inflammatory cytokine; resveratrol; severe burn; SIRT1

Indexed keywords

IL1B PROTEIN, MOUSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BIOSYNTHESIS; BLOOD; BURNS; C57BL MOUSE; CELL CULTURE; FEMALE; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MORTALITY; MOUSE; PATHOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SURVIVAL RATE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BURNS; CELLS, CULTURED; FEMALE; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SIRTUIN 1; STILBENES; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939982218     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0097-6     Document Type: Article

References (26)

1. Flierl, M.A., P.F. Stahel, B.M. Touban, K.M. Beauchamp, S.J. Morgan, W.R. Smith, and K.R. Ipaktchi. 2009. Bench-to-bedside review: burn-induced cerebral inflammation–a neglected entity? Critical Care 13: 215.
2. Bird, M.D., and E.J. Kovacs. 2008. Organ-specific inflammation following acute ethanol and burn injury. Journal of Leukocyte Biology 84: 607–613.
3. Hotchkiss, R.S., C.M. Coopersmith, J.E. McDunn, and T.A. Ferguson. 2009. The sepsis seesaw: tilting toward immune-suppression. Nature Medicine 15: 496–497.
4. Boomer, J.S., K. To, K.C. Chang, O. Takasu, D.F. Osborne, A.H. Walton, T.L. Bricker, S.D. Jarman 2nd, D. Kreisel, A.S. Krupnick, A. Srivastava, P.E. Swanson, J.M. Green, and R.S. Hotchkiss. 2011. Immuno-suppression in patients who die of sepsis and multiple organ failure. JAMA 306: 2594–2605.
5. Shi, W.W. 2010. The effect and mechanism of resveratrol potentiating the activity of anti-tumor drugs. Peking Union Medical College Hospital.
6. Zong, Y., L. Sun, B. Liu, Y.S. Deng, D. Zhan, Y.L. Chen, Y. He, J. Liu, Z.J. Zhang, J. Sun, and D. Lu. 2012. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One 7: e44107.
7. Baur, J.A., K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. Prabhu, J.S. Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. Lakatta, D. Le Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, and D.A. Sinclair. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
8. Liu, B., and Z. Zhou. 2013. Activation of SIRT1 by resveratrol requires lamin A. Aging (Albany NY) 5: 94–95.
9. Pearson, K.J., J.A. Baur, K.N. Lewis, L. Peshkin, N.L. Price, N. Labinskyy, W.R. Swindell, D. Kamara, R.K. Minor, E. Perez, H.A. Jamieson, Y. Zhang, S.R. Dunn, K. Sharma, N. Pleshko, L.A. Woollett, A. Csiszar, Y. Ikeno, D. Le Counteur, P.J. Elliott, K.G. Becker, P. Navas, D.K. Ingram, N.S. Wolf, Z. Ungvari, D.A. Sinclair, and R. de Cabo. 2008. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabolism 8: 157–168.
10. Borra, M.T., B.C. Smith, and J.M. Denu. 2005. Mechanism of human SIRT1 activation by resveratrol. Biological Chemistry 280: 17187–17195.
11. Hisahara, S., S. Chiba, H. Matsumoto, and Y. Horio. 2005. Transcriptional regulation of neuronal genes and its effect on neural functions DNA-dependent histone deacetylase SIRT1 (Sir2). Pharmacological Sciences 98: 200–204.
12. Leibiger, I.B., and P.O. Berggren. 2006. Sirt1: a metabolic master switch that modulates lifespan. Nature Medicine 12: 34–36.
13. Bordone, L., and L. Guarente. 2005. Caloric restriction, SIRT1 and metabolish: understanding longevity. Nature Reviews Molecular Cell Biology 6: 298–305.
14. Chua, K.F., R. Mostoslavsky, D.B. Lombard, W.W. Pang, S. Saito, S. Franco, D. Kaushal, H.L. Cheng, M.R. Fischer, N. Stokes, M.M. Murphy, E. Appella, and F.W. Alt. 2005. Mammalian SIRT1 limits replicative lifespan in response to chronic genotoxic stress. Cell Metabolism 2: 67–76.
15. Wang, T., J. Gu, P.F. Wu, F. Wang, Z. Xiong, Y.J. Yang, W.N. Wu, L.D. Dong, and J.G. Chen. 2009. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radical Biology and Medicine 47: 229–240.
16. Han, J.J., W. Liu, and Y.P. Bi. 2008. Advances in resveratrol studies. Chinese Journal of Biotechnology 24: 1851–1859.
17. Chen, H.X., X.X. Zhu, X. Xu, Y. Xue, X. Yang, and H.J. Zou. 2013. Research progress of Sirt1 in immune regulation. Progress in Modern Biomedicine 13: 2570–2573.
18. Niederer, F., C. Ospelt, F. Brentano, M.O. Hottiger, R.E. Gay, S. Gay, M. Detmar, and D. Kyburz. 2011. SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Annals of the Rheumatic Diseases 70: 1866–1873.
19. Stein, S., N. Schäfer, A. Breitenstein, C. Besler, S. Winnik, C. Lohmann, K. Heinrich, C.E. Brokopp, C. Handschin, U. Landmesser, F.C. Tanner, T.F. Lüscher, and C.M. Matter. 2010. SIRT1 reduce endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany NY) 2: 353–360.
20. Maria, J., R.D. Basterrechea, and M.D. Fernando Stein. 2000. Special article: the association of sepsis with multiple organ dysfunction syndrome. Seminars in Pediatric Infectious Diseases 1: 68–72.
21. Olholm, J., S.K. Paulsen, K.B. Cullberg, B. Richelsen, and S.B. Pedersen. 2010. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. International Journal of Obesity 34: 1546–1553.
22. Wang, S.J., Q.Y. Bo, X.H. Zhao, X. Yang, Z.F. Chi, and X.W. Liu. 2013. Resveratrol pre-treatment reduces early inflammatory responses induced by status epilepticus via mTOR signaling. Brain Research 1492: 122–129.
23. Gualdoni, A., J. Kovarik, J. Hofer, F. Dose, M. Pignitter, D. Doberer, P. Steinberger, V. Somoza, M. Wolzt, and G.J. Zlabinger. 2014. Resveratrol enhances TNF-αproduction inhuman monocytes bacterial stimulation. Biochemistry and Biophysics Acta 1840: 95–105.
24. Li, N., X. Hu, Y. Liu, Y. Wang, J. Liu, W. Cai, X. Bai, X. Zhu, J. Han, and D. Hu. 2013. Systemic inflammatory responses and multiple organ dysfunction syndrome following skin burn wound and pseudomonas aeruginosa infection in mice. Shock 40: 152–159.
25. Sulaiman, M., M.J. Matta, N.R. Sunderesan, M.P. Gupta, M. Periasamy, and M. Gupta. 2010. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 298: H833–H843.
26. Yoshizaki, T., S. Schenk, T. Imamura, J.L. Babendure, N. Sonoda, E.J. Bae, D.Y. Oh, M. Lu, J.C. Milne, C. Westphal, G. Bandyopadhyay, and J.M. Olefsky. 2010. SIRT1 inhabits inflammatory pathways in macrophages and modulates insulin sensitivity. American Journal of Physiology - Endocrinology and Metabolism 298: E419–E428.